|
Synonyms: E-01AJ | E-10030 | E01AJ | E10030 | Fovista® | X-01E | X01E
Compound class:
Nucleic acid
Comment: Pegpleranib (E10030) is a 32-mer pegylated DNA aptamer that selectively binds to PDGF-BB and PDGF-AB homo- and hetero-dimers. It prevents PDGF binding to its cognate PDGF receptors. Blocking receptor activation leads to the death of capillary pericytes. This mechanism was investigated as a disruptor of vessel formation in neovascular age related macular degeneration. Pegpleranib is formulated as a sodium adduct for therapeutic administration (see DBSALT002614).
|
| No information available. |
Summary of Clinical Use  |
| Phase 3 studies of E10030 were terminated when analyses showed that the combination of E10030 and ranibizumab (an anti-VEGFA mAb) failed to demonstrate enhanced efficacy (superiority) compared to ranibizumab alone. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT01940900 | A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Lucentis® Compared to Lucentis® Monotherapy | Phase 3 Interventional | Astellas Pharma Inc | The OPH1003 study | |
| NCT01940887 | A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Either Avastin® or Eylea® Compared to Avastin® or Eylea® Monotherapy | Phase 3 Interventional | Astellas Pharma Inc | The OPH1002 study | |
